Loading
Zilia
Zilia has developed a non-invasive platform technology that uses imaging, spectrometry and artificial intelligence to quantitatively measure different biomarkers in the human eye. Zilia’s initial product, Zilia Ocular, is the first retinal camera to quantify oxygen saturation, a crucial biomarker in ocular diseases such as glaucoma, DR and AMD. Zilia aims to revolutionize the prevention, diagnosis and management of these diseases by generating actionable data about the eye’s metabolic activity.
Funding
Every round, secondary, debt facility or acquisition involving Zilia that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—